- Home
- HOTH vs ALLR Comparison
HOTH vs ALLR Comparison
Compare HOTH & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- ALLR
- Stock Information
- Founded
- HOTH 2017
- ALLR 2004
- Country
- HOTH United States
- ALLR United States
- Employees
- HOTH 3
- ALLR N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- HOTH Health Care
- ALLR Health Care
- Exchange
- HOTH Nasdaq
- ALLR Nasdaq
- Market Cap
- HOTH 16.0M
- ALLR 15.8M
- IPO Year
- HOTH 2019
- ALLR N/A
- Fundamental
- Price
- HOTH $1.44
- ALLR $1.01
- Analyst Decision
- HOTH Strong Buy
- ALLR
- Analyst Count
- HOTH 3
- ALLR 0
- Target Price
- HOTH $4.00
- ALLR N/A
- AVG Volume (30 Days)
- HOTH 733.2K
- ALLR 413.4K
- Earning Date
- HOTH 05-12-2025
- ALLR 08-04-2025
- Dividend Yield
- HOTH N/A
- ALLR N/A
- EPS Growth
- HOTH N/A
- ALLR N/A
- EPS
- HOTH N/A
- ALLR N/A
- Revenue
- HOTH N/A
- ALLR N/A
- Revenue This Year
- HOTH N/A
- ALLR N/A
- Revenue Next Year
- HOTH N/A
- ALLR N/A
- P/E Ratio
- HOTH N/A
- ALLR N/A
- Revenue Growth
- HOTH N/A
- ALLR N/A
- 52 Week Low
- HOTH $0.58
- ALLR $0.61
- 52 Week High
- HOTH $3.80
- ALLR $7.45
- Technical
- Relative Strength Index (RSI)
- HOTH 62.68
- ALLR 53.22
- Support Level
- HOTH $1.17
- ALLR $0.95
- Resistance Level
- HOTH $1.34
- ALLR $1.08
- Average True Range (ATR)
- HOTH 0.10
- ALLR 0.07
- MACD
- HOTH 0.02
- ALLR 0.01
- Stochastic Oscillator
- HOTH 77.27
- ALLR 59.39
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.